VCYT (Veracyte, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by VCYT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | KARIN EASTHAM | Director | Sell | — | — |
| 2026-06-15 | ROBERT S EPSTEIN | Director | A | — | — |
| 2026-06-15 | Eliav Barr | Director | A | — | — |
| 2026-06-15 | Thomas F. Miller | Director | A | — | — |
| 2026-06-15 | Jens Holstein | Director | A | — | — |
| 2026-06-15 | EVAN/ FA JONES | Director | A | — | — |
| 2026-06-15 | David Brent Shafer | Director | A | — | — |
| 2026-06-15 | KARIN EASTHAM | Director | A | — | — |
| 2026-06-15 | Muna Bhanji | Director | A | — | — |
| 2026-06-04 | John Leite | Global Chief Commercial Off | MIXED | — | — |
| 2026-06-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | — | — |
| 2026-06-04 | Rebecca Chambers | Chief Financial Officer | MIXED | — | — |
| 2026-06-04 | Annie McGuire | EVP, General Counsel | MIXED | — | — |
| 2026-06-04 | Marc Stapley | Chief Executive Officer | MIXED | — | — |
| 2026-06-04 | Phillip G. Febbo | Chief Scientific & Med Officer | F | — | — |
| 2026-05-27 | Jonathan Wygant | VP, Chief Accounting Officer | MIXED | — | — |
| 2026-05-22 | ROBERT S EPSTEIN | Director | Sell | — | — |
| 2026-05-08 | Annie McGuire | SVP, General Counsel | Sell | — | — |
| 2026-04-14 | Kevin Richard Haas | Chief Dev and Tech Officer | A | — | — |
| 2026-03-10 | Rebecca Chambers | Chief Financial Officer | A | — | — |
| 2026-03-10 | Phillip G. Febbo | Chief Scientific & Med Officer | A | — | — |
| 2026-03-10 | Marc Stapley | Chief Executive Officer | A | — | — |
| 2026-03-10 | Jonathan Wygant | VP, Chief Accounting Officer | A | — | — |
| 2026-03-10 | John Leite | Chief Commercial Officer-CLIA | A | — | — |
| 2026-03-10 | Annie McGuire | SVP, General Counsel | A | — | — |
| 2026-03-06 | Marc Stapley | Chief Executive Officer | Sell | — | — |
| 2026-03-06 | John Leite | Chief Commercial Officer-CLIA | Sell | — | — |
| 2026-03-06 | Annie McGuire | SVP, General Counsel | Sell | — | — |
| 2026-03-06 | Rebecca Chambers | Chief Financial Officer | Sell | — | — |
| 2026-03-04 | Annie McGuire | SVP, General Counsel | F | — | — |
| 2026-03-04 | John Leite | Chief Commercial Officer-CLIA | F | — | — |
| 2026-03-04 | Marc Stapley | Chief Executive Officer | F | — | — |
| 2026-03-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | — | — |
| 2026-03-04 | Phillip G. Febbo | Chief Scientific & Med Officer | MIXED | — | — |
| 2026-03-04 | Rebecca Chambers | Chief Financial Officer | F | — | — |
| 2026-03-02 | Rebecca Chambers | Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | John Leite | Chief Commercial Officer-CLIA | MIXED | — | — |
| 2026-03-02 | Annie McGuire | SVP, General Counsel | MIXED | — | — |
| 2026-03-02 | Phillip G. Febbo | Chief Scientific & Med Officer | MIXED | — | — |
| 2026-03-02 | Marc Stapley | Chief Executive Officer | MIXED | — | — |
| 2025-12-17 | Annie McGuire | SVP, General Counsel | Sell | — | — |
| 2025-12-08 | KARIN EASTHAM | Director | MIXED | — | — |
| 2025-12-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | — | — |
| 2025-12-04 | John Leite | Chief Commercial Officer-CLIA | MIXED | — | — |
| 2025-12-04 | Marc Stapley | Chief Executive Officer | MIXED | — | — |
| 2025-12-04 | Annie McGuire | SVP, General Counsel | MIXED | — | — |
| 2025-12-04 | Phillip G. Febbo | Chief Scientific & Med Officer | F | — | — |
| 2025-12-04 | Rebecca Chambers | Chief Financial Officer | MIXED | — | — |
| 2025-11-26 | John Leite | Chief Commercial Officer-CLIA | Sell | — | — |
| 2025-11-26 | EVAN/ FA JONES | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,826,588 | — |
| — | Director | 3,594,989 | — |
| — | Director | 3,594,989 | — |
| — | 10%+ Owner | 3,551,929 | — |
| — | 10%+ Owner | 3,551,929 | — |
| — | Director | 3,551,929 | — |
| — | 10%+ Owner | 3,063,294 | — |
| — | 10%+ Owner | 3,063,294 | — |
| — | 10%+ Owner | 3,063,294 | — |
| — | 10%+ Owner | 3,063,294 | — |
| — | 10%+ Owner | 2,801,929 | — |
| — | Director | 1,233,289 | — |
| — | Chief Executive Officer | 578,545 | — |
| — | Chief Financial Officer | 176,841 | — |
| — | Director | 176,177 | — |
| — | Chief Scientific & Med Officer | 149,797 | — |
| — | Global Chief Commercial Off | 146,280 | — |
| — | EVP, General Counsel | 139,016 | — |
| — | COO / CFO | 116,858 | — |
| — | President, CLIA U.S. | 76,988 | — |
| — | Chief Commercial Officer | 73,844 | — |
| — | — | 71,728 | — |
| — | Chief Scientific & Med Officer | 65,970 | — |
| — | Director | 57,718 | — |
| — | Director | 56,461 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VCYT quote page; the site-wide leaderboard is on the insider transactions hub.